Institutional members access full text with Ovid®

Share this article on:

Abnormal Liver Test Results in Myotonic Dystrophy

Achiron, Anat M.D., Ph.D.; Barak, Yoram M.D.; Magal, Nurit Ph.D.; Shohat, Moti M.D.; Cohen, Maya M.D.; Barar, Rakefet M.D.; Gadoth, Natan M.D.

Journal of Clinical Gastroenterology: June 1998 - Volume 26 - Issue 4 - p 292-295
Original Studies

Myotonic dystrophy (DM) is an autosomal dominant multisystem disorder. Little evidence suggests the existence of liver damage in a small number of patients. We have prospectively evaluated liver and gallbladder function in 53 patients with DM in relation to clinical and genetic parameters. None of the patients had an enlarged liver, signs of cirrhosis, or portal hypertension. All were free of medication, and none were pregnant or had a history of alcohol abuse. In 35 (66%) patients, serum activity of at least one of six liver enzymes assayed was abnormal. An elevated level of alkaline phosphatase was found in 50.9%, of gamma-glutamyltransferase in 52.8%, of 5′ nucleotidase in 43.4%, of serum aspartate aminotransferase in 35.8%, of serum alanine aminotransferase in 33.9%, and of lactate dehydrogenase in 37.7%. Liver function test results did not correlate with severity of muscle weakness, disease duration, or serum levels of creatine kinase, glucose, or lipids. Motility of gallbladder and abdominal ultrasonography were normal. Cytosine-thymidine-guanine repeat expansion by southern blot did not correlate with liver enzyme abnormalities. We conclude that elevation of liver enzymes is frequent in DM and should be included as an additional laboratory finding of the disease.

From the Multiple Sclerosis Center (A.A., Y.B.), Sheba Medical Center, Tel-Hashomer; Medical Genetics Laboratory (N.M., M.S.), Felsenstein Research Center, Children's Medical Center, Petah-Tiqva; Departments of Radiology (M.C.) and Neurology (R.B., N.G.), Beilinson Medical Center, Petah-Tiqva, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.

Received August 5, 1997. Sent for revision November 6, 1997. Accepted January 15, 1998.

Address correspondence and reprint requests to Dr. Anat Achiron, Multiple Sclerosis Center, Sheba Medical Center, Tel-Hashomer, 52621, Israel.

© Lippincott-Raven Publishers